Latest news with #ThermoFisher
Yahoo
a day ago
- Business
- Yahoo
Mettler-Toledo (MTD) To Report Earnings Tomorrow: Here Is What To Expect
Precision measurement company Mettler-Toledo (NYSE:MTD) will be reporting results this Thursday after market hours. Here's what you need to know. Mettler-Toledo beat analysts' revenue expectations by 1% last quarter, reporting revenues of $883.7 million, down 4.6% year on year. It was a slower quarter for the company, with a miss of analysts' full-year EPS guidance estimates. Is Mettler-Toledo a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Mettler-Toledo's revenue to be flat year on year at $955.4 million, improving from the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $9.60 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Mettler-Toledo has missed Wall Street's revenue estimates three times over the last two years. Looking at Mettler-Toledo's peers in the research tools & consumables segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Thermo Fisher delivered year-on-year revenue growth of 3%, beating analysts' expectations by 1.6%, and Danaher reported revenues up 3.4%, topping estimates by 1.7%. Thermo Fisher traded up 11.3% following the results while Danaher was also up 5.3%. Read our full analysis of Thermo Fisher's results here and Danaher's results here. Investors in the research tools & consumables segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Mettler-Toledo is up 7.8% during the same time and is heading into earnings with an average analyst price target of $1,271 (compared to the current share price of $1,266). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
3 days ago
- Business
- Yahoo
Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025
Comprehensive portfolio—from women's health to allergy, autoimmune and oncology testing—advances laboratory processes through the ability to provide earlier and more efficient detection and diagnosis CHICAGO, July 28, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, showcases its innovations in improving clinical and diagnostic laboratory efficiency and workflow optimization during the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 27-31, 2025, in Chicago, Ill. The company debuts two new solutions, LabLink360™* and Thermo Scientific™ MAS™ Max quality controls, designed to support quality control assurance and streamline workflows in clinical laboratories. It also features its rapid next-generation sequencing (NGS) technology, recently approved by the U.S. Food and Drug Administration (FDA), the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer, for use as a companion diagnostic for Dizal's ZEGFROVY® (sunvozertinib) and for tumor profiling applications. "Our solutions harness our scientific expertise to enhance care by enabling earlier and more precise detection and diagnosis. In partnership with our customers, we're working every day to bring better, faster and safer diagnostics to all patients," said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. "At Thermo Fisher, we are committed to advancing diagnostics that address today's most pressing global health challenges by boosting efficiency and reducing overall laboratory costs — ultimately driving more optimal patient care." Harnessing Innovation for Quality Assurance, Efficiency and Sustainability in the Clinical Lab Clinical laboratories rely on quality assurance programs (QAPs) to ensure test result accuracy, which is essential for proper diagnosis and treatment. In resource-limited settings, a QAP that delivers quick, actionable insights can ease operational bottlenecks, improve workflow efficiency and enhance data-driven decisions. Thermo Fisher's new LabLink360 is a next-generation QAP software designed to help enhance patient safety, reduce errors and elevate healthcare quality. It features Sigma-metric analysis, a global benchmarking tool that helps labs assess performance and optimize quality control parameters based on results. Thermo Fisher also recently launched the Thermo Scientific MAS Omni•CORE™ Max load-and-go quality controls (QC) to help simplify and automate lab workflows, allowing lab technicians to be more efficient and focus more on delivering fast and accurate patient results. The Omni•CORE Max QCs are part of a portfolio of QCs for clinical diagnostic testing, including the MAS Diabetes Max, which can help labs reduce daily QC bottles by up to 54% and lot-to-lot validations by up to 77%.** Beyond supporting the improved efficiency of laboratories, Thermo Fisher is also committed to supporting customers' sustainability initiatives. While most labs print patient results, QC, calibrations and other instrument data and place them in storage, this practice contributes to a staggering environmental impact. The company will present a poster and a micro-lecture explaining the transformative benefits of transitioning to a paperless laboratory environment. Targeting Unmet Diagnostic Needs Approximately 85% of patients in the U.S. receive cancer care in community settings. However, these sites have historically lacked consistent access to rapid and reliable next-generation sequencing, which is playing a growing role in informing precision oncology treatment decisions. At ADLM, the company will present its rapid NGS solution, the Oncomine Dx Express Test on the Ion Torrent Genexus Integrated Sequencer. Available as both an RUO solution and for clinical use on the Genexus Dx System, more care teams can now access NGS results in as little as 24 hours*** to help make more informed treatment recommendations for their patients, while also sparing patients from unnecessary delays, procedures and uncertainty. Also helping expand vital testing the company will highlight its PreClara™ Ratio,**** cleared in 2023 and previously known as B·R·A·H·M·S™ sFlt-1/PlGF KRYPTOR™ Test System, which offers clarity in assessing the risk of developing preeclampsia with severe features in hospitalized pregnant women within two weeks of testing. As the first FDA-cleared biomarker test for preeclampsia risk assessment, the PreClara Ratio provides reliable, quantifiable results with excellent analytical and clinical performance. When combined with other laboratory tests and standard clinical assessment, the PreClara Ratio may enable more informed clinical decisions, with the aim of improving health outcomes for both mothers and their babies. Thermo Fisher will also highlight its EXENT® Solution, a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The EXENT Solution enables more sensitive analytical methods that can differentiate between patient subsets without requiring invasive bone marrow biopsy techniques too early. It is currently available for clinical use in Brazil, Belgium, France, Germany, Italy, the Netherlands, New Zealand, Spain, the United Kingdom, Switzerland and Australia. Thermo Fisher is also presenting its latest solutions for allergy and autoimmune diagnostics, oncology, women's health and quality control testing. In the booth, attendees can engage with a series of dynamic micro-lectures designed to advance industry knowledge and clinical expertise. These sessions cover a wide range of diagnostic topics and innovations, offering valuable insights into improving testing efficiency, patient outcomes and disease detection strategies. For more information on Thermo Fisher's activities at ADLM, please visit or conference booth (2812) to experience the full breadth of Thermo Fisher's diagnostic solutions. * Not yet commercially available.**Will vary for each laboratory depending on the configuration. Data on file.***Timing varies by number of samples and type of run.****Brand trademarked in the U.S. only. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on Contacts Media Contact Information:Jessika Parry, Greenough419-266-4016jparry@ Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Business Wire
3 days ago
- Business
- Business Wire
Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025
CHICAGO--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, showcases its innovations in improving clinical and diagnostic laboratory efficiency and workflow optimization during the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 27-31, 2025, in Chicago, Ill. The company debuts two new solutions, LabLink360™* and Thermo Scientific™ MAS™ Max quality controls, designed to support quality control assurance and streamline workflows in clinical laboratories. It also features its rapid next-generation sequencing (NGS) technology, recently approved by the U.S. Food and Drug Administration (FDA), the Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ Dx Integrated Sequencer, for use as a companion diagnostic for Dizal's ZEGFROVY® (sunvozertinib) and for tumor profiling applications. 'Our solutions harness our scientific expertise to enhance care by enabling earlier and more precise detection and diagnosis. In partnership with our customers, we're working every day to bring better, faster and safer diagnostics to all patients,' said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. 'At Thermo Fisher, we are committed to advancing diagnostics that address today's most pressing global health challenges by boosting efficiency and reducing overall laboratory costs — ultimately driving more optimal patient care.' Harnessing Innovation for Quality Assurance, Efficiency and Sustainability in the Clinical Lab Clinical laboratories rely on quality assurance programs (QAPs) to ensure test result accuracy, which is essential for proper diagnosis and treatment. In resource-limited settings, a QAP that delivers quick, actionable insights can ease operational bottlenecks, improve workflow efficiency and enhance data-driven decisions. Thermo Fisher's new LabLink360 is a next-generation QAP software designed to help enhance patient safety, reduce errors and elevate healthcare quality. It features Sigma-metric analysis, a global benchmarking tool that helps labs assess performance and optimize quality control parameters based on results. Thermo Fisher also recently launched the Thermo Scientific MAS Omni•CORE ™ Max load-and-go quality controls (QC) to help simplify and automate lab workflows, allowing lab technicians to be more efficient and focus more on delivering fast and accurate patient results. The Omni•CORE Max QCs are part of a portfolio of QCs for clinical diagnostic testing, including the MAS Diabetes Max, which can help labs reduce daily QC bottles by up to 54% and lot-to-lot validations by up to 77%.** Beyond supporting the improved efficiency of laboratories, Thermo Fisher is also committed to supporting customers' sustainability initiatives. While most labs print patient results, QC, calibrations and other instrument data and place them in storage, this practice contributes to a staggering environmental impact. The company will present a poster and a micro-lecture explaining the transformative benefits of transitioning to a paperless laboratory environment. Targeting Unmet Diagnostic Needs Approximately 85% of patients in the U.S. receive cancer care in community settings. However, these sites have historically lacked consistent access to rapid and reliable next-generation sequencing, which is playing a growing role in informing precision oncology treatment decisions. At ADLM, the company will present its rapid NGS solution, the Oncomine Dx Express Test on the Ion Torrent Genexus Integrated Sequencer. Available as both an RUO solution and for clinical use on the Genexus Dx System, more care teams can now access NGS results in as little as 24 hours*** to help make more informed treatment recommendations for their patients, while also sparing patients from unnecessary delays, procedures and uncertainty. Also helping expand vital testing the company will highlight its PreClara™ Ratio,**** cleared in 2023 and previously known as B·R·A·H·M·S™ sFlt-1/PlGF KRYPTOR™ Test System, which offers clarity in assessing the risk of developing preeclampsia with severe features in hospitalized pregnant women within two weeks of testing. As the first FDA-cleared biomarker test for preeclampsia risk assessment, the PreClara Ratio provides reliable, quantifiable results with excellent analytical and clinical performance. When combined with other laboratory tests and standard clinical assessment, the PreClara Ratio may enable more informed clinical decisions, with the aim of improving health outcomes for both mothers and their babies. Thermo Fisher will also highlight its EXENT ® Solution, a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The EXENT Solution enables more sensitive analytical methods that can differentiate between patient subsets without requiring invasive bone marrow biopsy techniques too early. It is currently available for clinical use in Brazil, Belgium, France, Germany, Italy, the Netherlands, New Zealand, Spain, the United Kingdom, Switzerland and Australia. Thermo Fisher is also presenting its latest solutions for allergy and autoimmune diagnostics, oncology, women's health and quality control testing. In the booth, attendees can engage with a series of dynamic micro-lectures designed to advance industry knowledge and clinical expertise. These sessions cover a wide range of diagnostic topics and innovations, offering valuable insights into improving testing efficiency, patient outcomes and disease detection strategies. For more information on Thermo Fisher's activities at ADLM, please visit or conference booth (2812) to experience the full breadth of Thermo Fisher's diagnostic solutions. * Not yet commercially available. ** Will vary for each laboratory depending on the configuration. Data on file. ***Timing varies by number of samples and type of run. ****Brand trademarked in the U.S. only. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
Yahoo
4 days ago
- Business
- Yahoo
What To Expect From Revvity's (RVTY) Q2 Earnings
Life sciences company Revvity (NYSE:RVTY) will be reporting results this Monday morning. Here's what you need to know. Revvity beat analysts' revenue expectations by 0.6% last quarter, reporting revenues of $664.8 million, up 2.3% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts' EPS estimates. Is Revvity a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Revvity's revenue to grow 3% year on year to $712.3 million, a reversal from the 2.5% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.14 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 5 downward revisions over the last 30 days (we track 14 analysts). Revvity has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.2% on average. Looking at Revvity's peers in the life sciences tools & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Thermo Fisher delivered year-on-year revenue growth of 3%, beating analysts' expectations by 1.6%, and Danaher reported revenues up 3.4%, topping estimates by 1.7%. Thermo Fisher traded up 11.3% following the results while Danaher was also up 5.3%. Read our full analysis of Thermo Fisher's results here and Danaher's results here. Investors in the life sciences tools & services segment have had steady hands going into earnings, with share prices flat over the last month. Revvity is up 6.2% during the same time and is heading into earnings with an average analyst price target of $121 (compared to the current share price of $103.91). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Business Wire
7 days ago
- Science
- Business Wire
Thermo Fisher Scientific Increases Accessibility to Research With the Launches of Scios 3 and Talos 12 Electron Microscopes at M&M 2025 Conference
BUSINESS WIRE)--As the world leader in serving science, Thermo Fisher Scientific is proud to announce the launch of two new electron microscopes that will be unveiled at Microscopy & Microanalysis (M&M) in Salt Lake City, Utah, July 27-31, each significantly contributing to the democratization of research in the sciences. Scios 3 FIB-SEM offers high-powered versatility The Thermo Scientific™ Scios™ 3 is a focused ion beam (FIB) scanning electron microscope (SEM) with automation to dramatically improve site-specific quality control. The Scios 3 FIB-SEM offers increased productivity for both industry and academia with enhanced lamella preparation, due to advances in FIB column performance. Ease-of-use upgrades will benefit microscopists of all experience levels. 'Researchers across the globe seek new and better materials for various applications – from clean energy and aerospace to productivity of digital devices,' said David Wall, vice president and general manager of materials science for Thermo Fisher. 'The current pace of the development of new materials and their increasing complexity poses significant challenges, and Scios 3 addresses those challenges head-on with world-class advancements designed to serve both academia and industry.' With advanced automation and high-throughput, Scios 3 improves ease of use, reliability and productivity. To learn more, stop by booth #1734 at M&M for a live demonstration or visit Talos 12 adapts to researchers across disciplines and experience levels Thermo Fisher has evolved the popular Talos transmission electron microscope (TEM) design, culminating in the Thermo Scientific Talos™ 12 TEM, making leading-edge sample analysis more accessible than ever for biological research, pathology and drug development. 'We're pleased to introduce Talos 12 at M&M this year to bring transmission electron microscopy to more researchers,' said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher. 'A wide array of laboratories can now benefit from this adaptable 120kV instrument. Not only does the reduced footprint and next-generation enclosure fit into more lab spaces, but the streamlined workflows – from routine imaging of cells and tissues to AI-assisted sample characterization to cryo-EM – enable the user-friendly Talos 12 to support remote operation for collaboration regardless of location.' TEM systems often require highly skilled specialists, but Talos 12 lowers those requirements with new enhancements to improve ease of use while maintaining high quality imaging with high reproducibility. To learn more, stop by booth #1734 at M&M for a live demonstration or visit Stop by booth #1734 to see Scios, Talos and more Thermo Fisher will have a significant presence at the Salt Palace Convention Center. In addition to live demonstrations of Scios 3 and Talos 12, several other industry-leading solutions will be on full display. Stop by booth #1734 to engage with Thermo Fisher subject-matter experts as they discuss the latest advancements in microscopy innovation and analytical research technology. Additionally, Thermo Fisher has hosted a 'Women in Microscopy' breakfast at M&M for more than two decades and will continue that tradition at the Hyatt Regency on the morning of July 30. Dr. Amelia Dempere, Director of the Nanoscale Research Facility (NRF) at the University of Florida, will talk about her career journey and the ever-increasing importance of women in research. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
